Tirzepatide first made headlines for the size of the weight changes seen in clinical trials. But some of the most interesting research on the compound in the last two years has had little to do with body weight on its own. Studies have looked at the liver, the heart and even breathing during sleep, and the results have turned tirzepatide into a reference compound across several areas of metabolic science.
A quick recap: what tirzepatide does
Tirzepatide is a dual agonist. It activates two receptors for gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both play roles in insulin release, appetite signalling and how the body handles energy. Combining them in one molecule produced larger effects in trials than GLP-1 activity alone, which is why tirzepatide is now used as a benchmark for newer compounds.
The liver
Fatty liver disease, now often called MASLD, and its more serious inflammatory form, MASH, are closely linked to obesity and type 2 diabetes. In the Phase 2 SYNERGY-NASH trial, published in the New England Journal of Medicine in 2024, a much higher proportion of participants on tirzepatide saw their MASH resolve without worsening liver scarring than those on placebo.
For researchers, this raises questions that cell and tissue models are well suited to explore, such as how much of the liver effect comes from weight loss and how much from direct signalling through the two receptors.
The heart
In the SUMMIT trial, also published in 2024, tirzepatide was studied in people with obesity and a type of heart failure known as heart failure with preserved ejection fraction (HFpEF). Participants on tirzepatide had fewer serious heart failure events and reported better symptoms and physical function than those on placebo.
A large cardiovascular outcomes trial, SURPASS-CVOT, has also compared tirzepatide with an established GLP-1 compound in people with type 2 diabetes and heart disease. Together, these studies have pushed cardiovascular research to the centre of the incretin field.
Sleep apnoea
One of the more unexpected areas of research has been obstructive sleep apnoea, where the airway repeatedly narrows or closes during sleep. In the SURMOUNT-OSA trials, participants with obesity and sleep apnoea had substantially fewer breathing interruptions per hour on tirzepatide than on placebo. It was a clear example of how a metabolic compound can affect conditions well beyond blood sugar and weight.
What this means for laboratory research
This widening body of evidence has made tirzepatide useful in a range of lab settings:
- Liver cell models studying fat build-up, inflammation and the early stages of scarring.
- Heart and blood vessel cell studies looking at the direct effects of GLP-1 and GIP signalling.
- Comparison studies setting tirzepatide against single GLP-1 agonists and newer triple agonists such as retatrutide.
A clear introduction to tirzepatide, how it works and how it compares with other incretin compounds is available in the Tirzepatide UK research guide.
Sourcing research-grade tirzepatide
Tirzepatide is licensed in the UK as a prescription medicine under the brand name Mounjaro. Separately, research chemical suppliers provide tirzepatide strictly for laboratory use. For that research to be meaningful, the compound needs to be verified. Look for:
- An independent certificate of analysis from a recognised lab such as Janoshik, tied to the specific batch.
- Purity of 98% or above with a stated peptide content.
- UK stock and fast, tracked delivery.
- Clear research-use-only labelling.
UK suppliers such as Revial Labs tirzepatide stock the compound in the UK, dispatch the same day and publish independent test results.
The bottom line
Tirzepatide is no longer just a weight-loss story. Research into the liver, the heart and sleep has turned it into one of the most versatile reference compounds in metabolic science, and laboratory work will be key to understanding exactly how its two receptor targets produce such wide-ranging effects.
This article is for information only. Tirzepatide supplied by research chemical companies is for laboratory research use only and is not for human consumption.